(ABBV) AbbVie Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ABBV) AbbVie Inc. Bundle
Unlock Strategic Clarity
This AbbVie Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it easier to assess strategy and capital allocation. This page already shows a real preview of the analysis, so you can review the format and content before purchase. Get the full version for the complete ready-to-use report.
Stars
SKYRIZI, about $11.7B sales
SKYRIZI posted about $11.7B in 2024 sales, up roughly 50% year over year, and remained one of AbbVie Inc.'s fastest growers. It leads in psoriasis and keeps gaining share in inflammatory bowel disease, with Crohn's disease and ulcerative colitis fueling the next leg. High growth plus top-tier scale makes SKYRIZI a clear Star in the BCG Matrix.
RINVOQ, about $6.0B sales
RINVOQ posted about $6.0 billion in 2024 net revenues, up roughly 50% year over year, and stayed one of AbbVie Inc.'s main immunology growth drivers. Its approved uses in rheumatoid arthritis, ulcerative colitis, Crohn's disease, and atopic dermatitis support broad demand. That mix of rapid growth and rising share fits a clear Star in the BCG matrix.
QULIPTA, over $1B sales
QULIPTA has crossed the $1B sales mark, showing rapid adoption in migraine prevention. AbbVie says the migraine market is still expanding, and QULIPTA’s daily oral profile helps it win share versus injectables. That mix of strong growth, scale, and category room supports Star status in the BCG Matrix.
VRAYLAR, about $3.3B sales
VRAYLAR delivered about $3.3 billion in sales and kept double-digit growth in 2024, showing strong demand in bipolar I disorder and schizophrenia. That scale, plus its growing CNS franchise, supports Star status in AbbVie Inc.'s BCG Matrix. One-line view: high growth and strong market share still point to a premium asset.
- ~$3.3B sales in 2024
- Double-digit growth
- Leads in bipolar I and schizophrenia
- Strong CNS scale
JUVÉDERM, leading dermal filler franchise
JUVÉDERM is AbbVie Inc.’s core aesthetics engine, and its premium hyaluronic-acid fillers keep strong global brand pull. Medical aesthetics demand is still expanding, so a high-share franchise in a growing category fits the Star quadrant. AbbVie’s 2025 focus stayed on premium injectables, where repeat use and doctor trust support pricing.
- Premium HA filler line
- Strong global brand share
- Growth market supports Star status
AbbVie’s Growth Engines Are Firing on All Cylinders
AbbVie Inc.’s Stars are SKYRIZI and RINVOQ, with 2024 sales of $11.7B and $6.0B, both up about 50% year over year. QULIPTA topped $1B and is still scaling in migraine prevention, while VRAYLAR hit about $3.3B with double-digit growth. JUVÉDERM stays a premium aesthetics winner in a growing market.
| Asset | 2024 Sales | Growth |
|---|---|---|
| SKYRIZI | $11.7B | ~50% |
| RINVOQ | $6.0B | ~50% |
| QULIPTA | >$1B | Rapid |
| VRAYLAR | $3.3B | Double-digit |
What is included in the product
Detailed Word Document
AbbVie’s BCG Matrix maps its portfolio to spot stars, cash cows, question marks, and dogs for smart capital allocation.
Editable Excel File
One-page BCG matrix for AbbVie Inc. to quickly pinpoint cash cows, stars, and weak spots.
Reference Sources
Provides a credible source trail for AbbVie Inc. data, helping users verify assumptions fast and make better decisions with less uncertainty.
Cash Cows
HUMIRA, about $9.0B sales
HUMIRA remains a Cash Cow for AbbVie Inc.: despite biosimilar erosion, it still generated about $9.0B in sales in 2024, even after a steep year-over-year decline. That is classic Cash Cow behavior: low growth, but very large absolute cash flow. It still helps fund AbbVie Inc.’s newer growth brands.
BOTOX Cosmetic, roughly $2B sales
BOTOX Cosmetic is AbbVie Inc.'s mature premium aesthetics franchise, with roughly $2B in annual sales and enduring share in a large, established market. Growth is slower than newer launches, but the brand still throws off strong margins and steady cash flow. That mix of high share, mature demand, and reliable profits fits a Cash Cow in the BCG Matrix.
IMBRUVICA, about $3.0B sales
IMBRUVICA is still a Cash Cow for AbbVie, with about $3.0 billion in sales and a strong base in CLL and SLL. But the franchise is mature: competition from newer BTK inhibitors and other therapies has slowed growth, so it is no longer a high-growth asset. Even so, its scale and cash generation keep it valuable.
CREON, about $2.3B sales
CREON, at about $2.3B in sales, fits AbbVie Inc.’s Cash Cow bucket: it is a long-running gastrointestinal brand with steady demand, a mature market, and durable cash flow. The brand’s scale and entrenched position point to low growth but high reliability, which is exactly what Cash Cows are meant to deliver.
- About $2.3B sales
- Mature GI market
- Steady demand, strong share
- High durability, solid cash generation
LINZESS, about $1.5B sales
LINZESS remains a mature but durable constipation franchise for AbbVie, with about $1.5B in annual sales and steady recurring demand from chronic GI patients. Growth is slower now, but the brand’s scale and long prescribing history keep cash flow strong, making it a clear Cash Cow in the BCG matrix.
- About $1.5B sales
- Stable, recurring demand
- Mature growth, strong cash flow
- Dependable AbbVie Cash Cow
AbbVie’s Cash Cows Keep the Growth Engine Funded
AbbVie Inc.’s Cash Cows are mature brands that still generate heavy cash: HUMIRA at about $9.0B, IMBRUVICA near $3.0B, CREON about $2.3B, LINZESS around $1.5B, and BOTOX Cosmetic near $2.0B in annual sales. They have low growth now, but their scale and margins keep cash flow strong. That cash helps fund AbbVie Inc.’s newer growth drugs.
| Brand | Sales | BCG fit |
|---|---|---|
| HUMIRA | $9.0B | Cash Cow |
| IMBRUVICA | $3.0B | Cash Cow |
Get Your Copy
AbbVie Inc. Reference Sources
You're previewing the exact AbbVie Inc. BCG Matrix document you'll receive after purchase. The full file is identical to this preview, with no hidden sections, watermarks, or demo content. Once purchased, it’s ready for immediate use in strategic planning, analysis, or presentations.
Dogs
RESTASIS, generic-heavy market
RESTASIS is a Dog: long-term generic entry has crushed pricing and volume, and AbbVie’s share is far below its exclusivity peak. The U.S. dry-eye market now has multiple Rx options, including Xiidra and Cequa, so growth is thin and competition is heavy. With weak economics and no clear rebound, RESTASIS stays a low-growth, low-return asset.
ORILISSA, declining endometriosis sales
ORILISSA is a Dog for AbbVie Inc.: AbbVie reported about $0.26 billion in 2024 net revenue, down from about $0.29 billion in 2023, and the brand has never scaled into a major franchise. Sales have been pressured by safety limits, payer friction, and competition in endometriosis care. That low-growth, low-share profile fits the Dog quadrant.
DUOPA and DUODOPA, niche Parkinson’s therapy
DUOPA/DUODOPA is a levodopa-carbidopa intestinal gel for a very small slice of advanced Parkinson’s patients with severe motor fluctuations. Parkinson’s affects about 1 million people in the US and over 10 million worldwide, but this therapy serves only a narrow, specialist-managed subgroup. That limited addressable pool and slow volume growth make it a Dog in AbbVie Inc.’s BCG matrix.
ALPHAGAN and COMBIGAN, mature glaucoma brands
ALPHAGAN and COMBIGAN are mature glaucoma brands in a slow-growing eye-care market, where older products face steady pressure from newer therapies and generics. Glaucoma affects about 3 million Americans, but the addressable pool is stable, so growth is limited. That fits the Dogs bucket in AbbVie Inc.'s BCG Matrix.
- Older brands with low growth
- Generic and new-drug competition
- Stable demand, weak upside
- Cash flow, not expansion drivers
MAVYRET, shrinking HCV market
MAVYRET sits in a structurally shrinking hepatitis C market: direct-acting antivirals still cure over 95% of patients, but the untreated pool keeps falling as easier cases were already treated and new diagnoses stay low. AbbVie Inc. has said HCV is a declining franchise, so MAVYRET brings cash but little growth. In BCG terms, that makes it a Dog: mature, low-growth, and hard to expand.
- High cure rates limit repeat demand
- Patient pool keeps contracting
- Cash flow exists, growth does not
AbbVie’s Dogs: Cash-Flowing Legacy Brands, But No Growth Engine
AbbVie Inc.’s Dogs are mainly legacy, low-growth brands with shrinking pricing power: RESTASIS faces generic erosion, ORILISSA fell to about $0.26B in 2024 net revenue, and MAVYRET sits in a declining hepatitis C market. DUOPA/DUODOPA and ALPHAGAN/COMBIGAN also serve narrow or mature niches, so volume upside is limited. These assets still throw off cash, but they are not growth engines.
| Asset | 2024 signal | BCG fit |
|---|---|---|
| RESTASIS | Generic pressure | Dog |
| ORILISSA | $0.26B revenue | Dog |
| MAVYRET | Declining HCV pool | Dog |
Question Marks
VENCLEXTA, about $2.3B sales
VENCLEXTA delivered about $2.3 billion in AbbVie 2025 sales, so it still has meaningful scale, but the oncology market is crowded and hard to win in. Hematology demand remains active, yet share gains are slower than in AbbVie’s immunology blockbusters, which have far larger growth engines. That mix of real sales and uncertain upside makes VENCLEXTA a Question Mark in the BCG matrix.
UBRELVY, migraine acute market
UBRELVY is still growing, but AbbVie is fighting a crowded acute migraine market led by long-used triptans and newer CGRP rivals. AbbVie reported UBRELVY sales above $1 billion in the latest fiscal year, but share is still being built, not yet dominant. High growth plus a still-developing position fits a Question Mark.
ELAHERE, ovarian cancer launch
ELAHERE is still a young oncology launch, aimed at FRα-positive platinum-resistant ovarian cancer, a 2025 U.S. market of about 20,890 new cases and 12,730 deaths. Adoption is early versus AbbVie Inc.'s big cancer brands, but testing uptake and label breadth can keep the addressable pool expanding. That mix of small share and high upside fits a Question Mark.
EPKINLY, hematology expansion phase
EPKINLY is still in AbbVie Inc.'s early build phase, but its label is widening across more lymphoma settings, which lifts the addressable market fast. AbbVie reported EPKINLY net revenues of about $349 million in 2024, up sharply from launch, but that is still small versus the multi-billion-dollar lymphoma pool. That mix of fast opportunity growth and early penetration fits Question Mark territory.
Label expansion is the key growth driver.
Commercial sales are still early-stage.
Market size is larger than current revenue.
LILETTA, growing IUD franchise
LILETTA is a growing women’s health asset for AbbVie, but it still trails the category leaders in the contraceptive IUD market. That mix of high growth and lower share fits the BCG Question Marks bucket, as AbbVie is still building scale and adoption. The franchise can move up if share gains keep pace with market growth.
- High growth
- Lower share
- Still building scale
AbbVie’s Growth Bets Are Scaling, But Still Early
AbbVie Inc.'s Question Marks are VENCLEXTA, UBRELVY, ELAHERE, EPKINLY, and LILETTA: each has growth, but share is still not dominant. VENCLEXTA brought about $2.3 billion in 2025 sales, UBRELVY was above $1 billion, and EPKINLY was about $349 million in 2024, showing scale but still early positioning. ELAHERE and LILETTA are still building adoption, so their upside depends on faster penetration.
| Asset | Signal | Latest value |
|---|---|---|
| VENCLEXTA | Scale, but crowded | $2.3B 2025 |
| UBRELVY | Growing share | >$1B 2025 |
| EPKINLY | Early launch | $349M 2024 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.